To main content (press Enter)
(C) Univercells Two researchers doing manipulations in an incubator

Univercells writes a new biomanufacturing chapter with Africa

Belgian biotech company Univercells Group multiplies projects and collaborations with global partners to achieve its purpose: making biologics accessible for everyone, especially in low-and-middle income countries. From training in Kenya to the implementation of a mRNA production platform in South-Africa, Univercells Group provides, through its various entities, a fully-integrated expertise in biomanufacturing.

Manufacturing affordable Measles and Rubella vaccine in Senegal

On October 24th, 2022, Institut Pasteur de Dakar (IPD) announced the launch of a new program to advance the development of a measles and rubella vaccine for manufacture in Senegal. Thanks to a grant from the Bill & Melinda Gates Foundation, IPD is using Univercells Technologies’ proprietary platform (NevoLine™ Upstream) together with Batavia Biosciences’ production process for GMP measles and rubella material to accelerate manufacturing and affordable access to essential and epidemic vaccines in Africa. The new facility will have the capacity to produce 300 million doses of vaccine.

Supporting the development of the first African-owned mRNA COVID-19 vaccine in South-Africa

One year since the establishment of the mRNA Vaccine Technology Transfer Hub in Cape Town, Univercells Group - and its partner specialized in mRNA eTheRNA - announces concrete results from its new collaboration with Afrigen Biologics in Cape Town to develop the first-ever African-owned mRNA COVID-19 vaccine. This collaboration is meant to provide local cost-effective vaccine production (currently African countries import 99% of all the vaccines they use) as well as affordable cold-storage and distribution which are two major challenges that need to be addressed to ensure vaccination for the African populations, even in rural and remote locations.

Initiating a new biomanufacturing training program in Kenya

Africa is on its way to significantly increase its vaccine production. Its objective? Delivering 1.5 billion doses per year by 2040. In this context, Kenya healthcare and research leaders are building the training and ecosystem to ensure that end-to-end research, development and manufacturing of biologics can become a reality for the country.

As one of the key international partners of the biomanufacturing training hub, Unizima, an affiliate of Univercells Group, will provide expertise, advisory support, training as well as technology transfer.


Interested in updates on our
insights, news and testimonials?